PULMONX CORP(NASDAQ:LUNG) stock Fundamental Analysis

Fundamental Rating

Taking everything into account, LUNG scores 3 out of 10 in our fundamental rating. LUNG was compared to 191 industry peers in the Health Care Equipment & Supplies industry. While LUNG seems to be doing ok healthwise, there are quite some concerns on its profitability. LUNG is valued quite expensive, but it does show an excellent growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year LUNG has reported negative net income.

LUNG had a negative operating cash flow in the past year.

In the past 5 years LUNG always reported negative net income.

LUNG had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

LUNG has a Return On Assets (-34.63%) which is in line with its industry peers.

The Return On Equity of LUNG (-65.72%) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-34.63%
ROE	-65.72%
ROIC	N/A

ROA(3y)-33.09%

ROA(5y)-26.44%

ROE(3y)-51.8%

ROE(5y)-38.97%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 74.00%, LUNG belongs to the best of the industry, outperforming 84.82% of the companies in the same industry.

In the last couple of years the Gross Margin of LUNG has remained more or less at the same level.

The Profit Margin and Operating Margin are not available for LUNG so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	74%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.19%

GM growth 5Y1.48%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

LUNG does not have a ROIC to compare to the WACC, probably because it is not profitable.

LUNG has more shares outstanding than it did 1 year ago.

The number of shares outstanding for LUNG has been increased compared to 5 years ago.

The debt/assets ratio for LUNG is higher compared to a year ago.

2.2 Solvency

LUNG has an Altman-Z score of -2.32. This is a bad value and indicates that LUNG is not financially healthy and even has some risk of bankruptcy.

LUNG has a Altman-Z score of -2.32. This is in the lower half of the industry: LUNG underperforms 61.78% of its industry peers.

A Debt/Equity ratio of 0.40 indicates that LUNG is not too dependend on debt financing.

LUNG has a Debt to Equity ratio (0.40) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0.4
Debt/FCF	N/A
Altman-Z	-2.32

ROIC/WACCN/A

WACC9.47%

2.3 Liquidity

LUNG has a Current Ratio of 5.58. This indicates that LUNG is financially healthy and has no problem in meeting its short term obligations.

LUNG's Current ratio of 5.58 is amongst the best of the industry. LUNG outperforms 81.15% of its industry peers.

A Quick Ratio of 4.88 indicates that LUNG has no problem at all paying its short term obligations.

LUNG has a better Quick ratio (4.88) than 80.10% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	5.58
Quick Ratio	4.88

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.50% over the past year.

LUNG shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.00%.

Measured over the past years, LUNG shows a very strong growth in Revenue. The Revenue has been growing by 20.78% on average per year.

EPS 1Y (TTM)12.5%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%8.33%

Revenue 1Y (TTM)22%

Revenue growth 3Y20.06%

Revenue growth 5Y20.78%

Sales Q2Q%23.28%

3.2 Future

Based on estimates for the next years, LUNG will show a very strong growth in Earnings Per Share. The EPS will grow by 29.25% on average per year.

Based on estimates for the next years, LUNG will show a very strong growth in Revenue. The Revenue will grow by 32.15% on average per year.

EPS Next Y-12.67%

EPS Next 2Y-1.33%

EPS Next 3Y7.36%

EPS Next 5Y29.25%

Revenue Next Year17.73%

Revenue Next 2Y18.3%

Revenue Next 3Y20.43%

Revenue Next 5Y32.15%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

LUNG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year LUNG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-1.33%

EPS Next 3Y7.36%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

LUNG does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PULMONX CORP

NASDAQ:LUNG (4/23/2025, 4:30:01 PM)

After market: 4.99 0 (0%)

4.99

+0.23 (+4.83%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)02-19 2025-02-19/amc

Earnings (Next)04-30 2025-04-30/amc

Inst Owners94.24%

Inst Owner Change0.02%

Ins Owners4.75%

Ins Owner Change7.05%

Market Cap200.85M

Analysts80

Price Target12.68 (154.11%)

Short Float %3.3%

Short Ratio3.82

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)24.5%

Min EPS beat(2)21.31%

Max EPS beat(2)27.7%

EPS beat(4)4

Avg EPS beat(4)22.95%

Min EPS beat(4)19.29%

Max EPS beat(4)27.7%

EPS beat(8)8

Avg EPS beat(8)15.71%

EPS beat(12)11

Avg EPS beat(12)11.08%

EPS beat(16)15

Avg EPS beat(16)11.64%

Revenue beat(2)1

Avg Revenue beat(2)1.52%

Min Revenue beat(2)-1.48%

Max Revenue beat(2)4.53%

Revenue beat(4)3

Avg Revenue beat(4)1.89%

Min Revenue beat(4)-1.48%

Max Revenue beat(4)4.53%

Revenue beat(8)7

Avg Revenue beat(8)3.57%

Revenue beat(12)9

Avg Revenue beat(12)3.28%

Revenue beat(16)11

Avg Revenue beat(16)3.59%

PT rev (1m)6.53%

PT rev (3m)7.3%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-1.19%

EPS NY rev (1m)3.17%

EPS NY rev (3m)3.17%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-0.86%

Revenue NY rev (1m)0.02%

Revenue NY rev (3m)-0.83%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	2.4
P/FCF	N/A
P/OCF	N/A
P/B	2.34
P/tB	2.41
EV/EBITDA	N/A

EPS(TTM)-1.4

EYN/A

EPS(NY)-1.58

Fwd EYN/A

FCF(TTM)-0.82

FCFYN/A

OCF(TTM)-0.78

OCFYN/A

SpS2.08

BVpS2.13

TBVpS2.07

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-34.63%
ROE	-65.72%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	74%
FCFM	N/A

ROA(3y)-33.09%

ROA(5y)-26.44%

ROE(3y)-51.8%

ROE(5y)-38.97%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.19%

GM growth 5Y1.48%

F-Score3

Asset Turnover0.51

Health

		Industry Rank	Sector Rank
Debt/Equity	0.4
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	96.92%
Cap/Sales	1.73%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	5.58
Quick Ratio	4.88
Altman-Z	-2.32

F-Score3

WACC9.47%

ROIC/WACCN/A

Cap/Depr(3y)78.82%

Cap/Depr(5y)169.58%

Cap/Sales(3y)1.79%

Cap/Sales(5y)3.14%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)12.5%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%8.33%

EPS Next Y-12.67%

EPS Next 2Y-1.33%

EPS Next 3Y7.36%

EPS Next 5Y29.25%

Revenue 1Y (TTM)22%

Revenue growth 3Y20.06%

Revenue growth 5Y20.78%

Sales Q2Q%23.28%

Revenue Next Year17.73%

Revenue Next 2Y18.3%

Revenue Next 3Y20.43%

Revenue Next 5Y32.15%

EBIT growth 1Y9.58%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year34.21%

EBIT Next 3Y17.16%

EBIT Next 5Y8.62%

FCF growth 1Y14.14%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y16.15%

OCF growth 3YN/A

OCF growth 5YN/A

PULMONX CORP (LUNG) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens